论文部分内容阅读
目的:评价重组人血小板生成素(rhTPO)治疗肿瘤化疗后血小板减少的疗效和不良反应。方法:采用自身对照交叉研究方法,对第1周期(对照组)化疗后血小板(PLT)≤75×109/L的38例实体肿瘤患者于第2周期采用相同化疗方案,随机分为A组和B组(治疗组),每组19例。A组:第2周期化疗前3天开始皮下注射rhTPO(15 000U),每日1次,连用7 d;B组:第2周期化疗结束后6~24 h注射rhTPO(15 000 U),每日1次,连用7 d。结果:与对照组相比,A组和B组血小板减少程度和持续时间差异有统计学意义(P<0.05);A组与B组比较,血小板最低值、血小板≤50×109/L持续时间及血小板恢复至≥100×109/L时间差异有统计学意义(P<0.01)。结论:rhTPO可减少PLT降低程度和持续时间,提前给药效果更佳,且无严重不良反应。
Objective: To evaluate the efficacy and adverse reactions of recombinant human thrombopoietin (rhTPO) in the treatment of thrombocytopenia after chemotherapy. METHODS: Using the self-control crossover study method, 38 patients with solid tumors with platelet (PLT) ≤75×109/L after the first cycle (control group) were treated with the same chemotherapy regimen in the second cycle and were randomly divided into group A and Group B (treatment group), 19 cases in each group. Group A: rhTPO (15 000 U) was injected subcutaneously 3 days before the second cycle of chemotherapy, once daily for 7 days; Group B: rhTPO (15 000 U) was injected 6-24 h after the end of the second cycle of chemotherapy. Once a day, use 7 days. RESULTS: Compared with the control group, the difference in the degree and duration of thrombocytopenia between group A and group B was statistically significant (P<0.05); the lowest platelet value and platelet ≤50×109/L duration were compared between group A and group B. And platelet recovery to ≥ 100 × 109 / L time difference was statistically significant (P <0.01). Conclusion: rhTPO can reduce the extent and duration of PLT reduction, and it is better for early administration and no serious adverse reactions.